Latest From Wockhardt Ltd.
Wockhardt has received approvals in India for two novel broad spectrum antibiotics with "advantageous" safety features over older MRSA drugs and the firm hopes to take them to other emerging markets as well, with China on the radar.
A look at corporate acquisitions and private equity deals in the Indian pharmaceutical industry over 2010-2019 reveals some trends, lessons and targets for possible activity in 2020.
Roche will obtain options to license candidates discovered and optimized by Rheos under the collaboration. Jazz acquires US rights to PharmaMar SCLC candidate, while Biogen teams with both Ionis and Catalyst.
Abbott is developing an extended release version of vildagliptin in India, adding a new dimension to the market dynamics for the DPP-4 inhibitor, which has seen a key patent expire. Sustained release vildagliptin products from Wockhardt and Synokem also appear to be in the works.
- Generic Drugs
- OTC, Consumer
- Therapeutic Areas
- Parent & Subsidiaries
- Wockhardt Ltd.
- Senior Management
Habil Khorakiwala, Chmn.
Rajiv Gandhi, Dir., Corp. Fin.
Yatendra Kumar, Pres., R&D, Reg, & QA
- Contact Info
Phone: (91) 22 2653 4444
Bandra Kurla Complex
Banda East, 400 051
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.